Mobile

A TWO-ARM RANDOMIZED OPEN LABEL PHASE 2 STUDY OF CP-751,871 IN COMBINATION WITH EXEMESTANE VERSUS EXEMESTANE ALONE AS FIRST LINE TREATMENT FOR POSTMENOPAUSAL PATIENTS WITH HORMONE RECEPTOR POSITIVE...

Update Il y a 4 ans
Reference: EUCTR2006-005573-21

A TWO-ARM RANDOMIZED OPEN LABEL PHASE 2 STUDY OF CP-751,871 IN COMBINATION WITH EXEMESTANE VERSUS EXEMESTANE ALONE AS FIRST LINE TREATMENT FOR POSTMENOPAUSAL PATIENTS WITH HORMONE RECEPTOR POSITIVE ADVANCED BREAST CANCER

Woman Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

To compare the efficacy, in terms of progression free survival (PFS), of CP-751,871 in combination with exemestane versus exemestane alone as first line treatment for hormone-dependent advanced breast cancer in postmenopausal women.

Inclusion criteria

  • Hormone receptor positive advanced breast cancer in postmenopausal women

Links